Kura Oncology: Safety Profile Of Komzifti Supports My Upgrade To Strong Buy [Seeking Alpha]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Seeking Alpha
Komzifti's FDA approval for relapsed/refractory NPM1-mutated AML is de-risked; the true equity upside lies in frontline AML expansion. Recent data show high remission rates and a favorable safety profile for Komzifti in frontline combinations, supporting the strategic thesis. At ~$8/share, Kura can appreciate if commercial ramp and/or frontline AML potential is confirmed. tomasz3d2/iStock via Getty Images On December 4, 2025, I initiated coverage of Kura Oncology ( KURA in this article with a Speculative Buy rating. The core of that thesis was straightforward. Kura is an early commercial stage biotech. In November 2025, the FDA This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha).
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion [Yahoo! Finance]Yahoo! Finance
- What Moved Markets This Week [Seeking Alpha]Seeking Alpha
- Kura Oncology (NASDAQ:KURA) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Kura Oncology price target lowered to $20 from $25 at Leerink [Yahoo! Finance]Yahoo! Finance
- Kura Oncology (NASDAQ:KURA) was given a new $20.00 price target on by analysts at Leerink Partners.MarketBeat
KURA
Earnings
- 11/4/25 - Miss
KURA
Sec Filings
- 1/29/26 - Form 8-K
- 1/27/26 - Form 4
- 1/27/26 - Form 4
- KURA's page on the SEC website